(DSGN) Design Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US25056L1035
DSGN: Drugs, Therapeutics, Medicines, Treatments
Design Therapeutics, Inc. (NASDAQ:DSGN) is a clinical-stage biopharmaceutical company specializing in the research, design, development, and commercialization of small molecule therapeutic drugs for genetic diseases. Leveraging its proprietary GeneTAC platform, the company focuses on developing treatments for inherited diseases caused by nucleotide repeat expansions. Its pipeline includes lead candidates for Friedreichs Ataxia, a progressive multi-system disease impacting mitochondrial function; Myotonic Dystrophy Type-1, a neuromuscular disorder affecting muscle, heart, and brain; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease causing progressive vision loss; and Huntingtons Disease, a neurodegenerative disorder characterized by movement, cognitive, and psychiatric impairments. Founded in 2017, the company is headquartered in Carlsbad, California.
As of the latest data, DSGN trades at $4.86 with a 20-day average volume of 142,599. The stock is currently near its 20-period simple moving average (SMA) of 4.51, slightly below its 50-period SMA of 5.11, and aligned with its 200-period SMA of 4.94. The Average True Range (ATR) of 0.41 indicates moderate volatility. The company has a market capitalization of $268.38M, with a price-to-book (P/B) ratio of 1.06 and a return on equity (RoE) of -18.93.
Additional Sources for DSGN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DSGN Stock Overview
| Market Cap in USD | 264m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2021-03-26 |
DSGN Stock Ratings
| Growth Rating | -65.1 |
| Fundamental | -37.6 |
| Dividend Rating | 0.0 |
| Rel. Strength | -14.4 |
| Analysts | 3.33/5 |
| Fair Price Momentum | 2.27 USD |
| Fair Price DCF | - |
DSGN Dividends
No Dividends PaidDSGN Growth Ratios
| Growth Correlation 3m | -46.5% |
| Growth Correlation 12m | 9.7% |
| Growth Correlation 5y | -81.4% |
| CAGR 5y | -45.02% |
| CAGR/Max DD 5y | -0.47 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -38.86 |
| Beta | 1.507 |
| Volatility | 103.31% |
| Current Volume | 72.3k |
| Average Volume 20d | 116.9k |
As of May 09, 2025, the stock is trading at USD 3.52 with a total of 72,252 shares traded.
Over the past week, the price has changed by -25.27%, over one month by +19.32%, over three months by -17.37% and over the past year by -24.95%.
Probably not. Based on ValueRay Fundamental Analyses, Design Therapeutics (NASDAQ:DSGN) is currently (May 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -37.57 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DSGN as of May 2025 is 2.27. This means that DSGN is currently overvalued and has a potential downside of -35.51%.
Design Therapeutics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold DSGN.
- Strong Buy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DSGN Design Therapeutics will be worth about 2.7 in May 2026. The stock is currently trading at 3.52. This means that the stock has a potential downside of -24.43%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 7.3 | 108.2% |
| Analysts Target Price | 7.3 | 108.2% |
| ValueRay Target Price | 2.7 | -24.4% |